Inmarsat Extends Partnership With CSG To Empower Cloud-Based Monetisation of Its Mobile Broadband Services
4.11.2020 11:00:00 EET | Business Wire | Press release
CSG ® (NASDAQ: CSGS) today announced that it has expanded its relationship with Inmarsat, a leader in global, mobile satellite communications. As part of this multi-year agreement, Inmarsat is moving its billing and revenue management operations to a consolidated, cloud-based managed services model developed by CSG, replacing existing third-party and bespoke legacy solutions.
“For nearly 20 years, CSG has worked with Inmarsat to get the most out of our billing and revenue management operations, enabling the introduction of new products and services while increasing efficiencies across our business,” said David Thornhill, senior vice president, Group IT Inmarsat. “By moving to a cloud-based managed services model, CSG will foster a more agile, cost-effective approach to how we operate our retail and wholesale business while creating a sustainable model for future success."
By utilising the CSG managed services solution, the British operator will benefit from increased process agility, go-to-market flexibility, and access to precision insights across all operations, while streamlining billing operations and lowering operating expenditures that were associated with prior third-party solutions.
The new agreement deploys the latest versions of CSG Singleview, CSG Interconnect, and CSG Intermediate, already in use by Inmarsat, helping them maximise profitability, reduce operational costs, and meet customer demands in real-time. Additional capabilities facilitate proactive identification and resolution of customer issues. In its entirety, the new cloud-based solution provides a future-proof architecture that takes advantage of best practices in billing and revenue management and enhances the customer experience.
“As Inmarsat looks to advance satellite, airborne, and maritime connectivity across Europe and beyond, we look forward to continuing our long-standing partnership, supporting the optimisation of their billing and revenue management operations, while helping them minimise risk and lower operating costs,” said James Kirby, head of CSG's EMEA business. “We are thrilled to expand our relationship with Inmarsat to help grow the business across their entire portfolio.”
CSG is recognised as a leader in the Gartner Magic Quadrant for its Revenue and Customer Management solutions, supporting hundreds of millions of end-users worldwide. The company provides monetisation, settlement and customer care solutions that help clients launch innovative digital services while transitioning off legacy systems at their own pace. CSG’s Wholesale Business Management Solution has won multiple awards for its cloud functionality and innovation and received the Global Stratecast CSP Monetisation Interconnect & Settlement Market Leadership Award from Frost & Sullivan in recent years.
About CSG
For more than 35 years, CSG has simplified the complexity of business, delivering innovative customer engagement solutions that help companies acquire, monetise, engage, and retain customers. Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually, and its award-winning suite of software and services allow companies across dozens of industries to tackle their biggest business challenges and thrive in an ever-changing marketplace.
CSG is the trusted partner for driving digital innovation for hundreds of leading global brands, including AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn and Twitter.
Copyright © 2020 CSG Systems International, Inc. and/or its affiliates (“CSG”). All rights reserved. CSG® is a registered trademark of CSG Systems International, Inc. All third-party trademarks, service marks, and/or product names which are referenced in this document are the property of their respective owners, and all rights therein are reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005049/en/
Contact information
Brad Jones
Global / North America / Asia-Pacific Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com
Kristine Østergaard
CSG
Europe / Middle East / Africa Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com
Liz Bauer
Investor Relations
CSG
+1 (303) 804-4065
liz.bauer@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom